| 摘要 |
<p>Methods and compositions are disclosed utilizing the optically pure (-) isomer of doxazosin. This compound is a potent drug for the treatment of benign prostatic hyperplasia while avoiding the concomitant liability of hypotensive effects associated with the racemic mixture of doxazosin. The optically pure (-) isomer of doxazosin is also useful for the treatment and prevention of atherosclerosis and other conditions related to elevated serum LDL and cholesterol levels, such as coronary artery disease, without the concomitant liability of adverse effects associated with the racemic mixture of doxazosin.</p> |
